Literature DB >> 1685014

Pharmacologic evidence that a D2 receptor subtype mediates dopaminergic stimulation of prolactin secretion from the anterior pituitary gland.

T P Burris1, L C Stringer, M E Freeman.   

Abstract

The ability of low concentrations of dopamine (DA) to stimulate the secretion of prolactin (PRL) was examined in perifused or monolayer cultures of anterior pituitary cells. In cultures perifused with media containing 100 nM DA, changing the DA concentration to either 1 or 100 pM caused a significant dose-dependent stimulatory PRL secretory response within 6 min when compared to the PRL secretory response to removal of DA altogether. Picomolar concentrations of DA caused a biphasic PRL secretory response. This response is characterized by an immediate increase in the rate of PRL secretion similar to that seen when the cells were treated with 100 nM thyrotropin-releasing hormone followed by a decrease in the rate of PRL secretion to levels comparable to cells receiving media alone. In a monolayer culture system DA, at concentrations between 10 nM and 1.0 pM, caused significant stimulation of PRL secretion relative to media alone. Maximal stimulation occurred at nanomolar concentrations of DA (approximately 60% greater than control). Although the D2 agonists, bromocriptine and 2-(N-phenethyl-N-propyl)-amino-5-hydroxytetralin hydrochloride (PPHT) caused significant (p less than 0.05) inhibition of PRL secretion at nanomolar concentrations and above, neither had stimulatory activity. The D1 agonists, SKF 38393 and SKF 82958, had no effect on PRL secretion when tested at 0.1 pM to 1 microM. These data suggest that DA not only inhibits PRL secretion in vitro, but also stimulates PRL secretion at relatively low concentrations. Stimulation is mediated by a DA receptor which is neither recognized by D2 nor D1 agonists, suggesting a possible third DA receptor subtype.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1685014     DOI: 10.1159/000125866

Source DB:  PubMed          Journal:  Neuroendocrinology        ISSN: 0028-3835            Impact factor:   4.914


  8 in total

Review 1.  Benefits and limitations of drug studies in temperament research: biochemical responses as indicators of temperament.

Authors:  Petra Netter
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2018-04-19       Impact factor: 6.237

2.  Low dose of dopamine may stimulate prolactin secretion by increasing fast potassium currents.

Authors:  Joël Tabak; Natalia Toporikova; Marc E Freeman; Richard Bertram
Journal:  J Comput Neurosci       Date:  2007-04       Impact factor: 1.621

3.  Dopamine D2 receptor mediates both inhibitory and stimulatory actions on prolactin release.

Authors:  A Chang; S H Shin; S C Pang
Journal:  Endocrine       Date:  1997-10       Impact factor: 3.633

4.  Effects of the estrous cycle stage on the prolactin secretory response to dopamine in vitro.

Authors:  C A Fitch; M E Freeman
Journal:  Endocrine       Date:  1996-02       Impact factor: 3.633

Review 5.  Dopamine resistance of prolactinomas.

Authors:  Mark E Molitch
Journal:  Pituitary       Date:  2003       Impact factor: 4.107

6.  Relationships between dopamine-induced changes in cytosolic free calcium concentration ([Ca2+]i) and rate of prolactin secretion. Elevated [Ca2+]i does not indicate prolactin release.

Authors:  A Chang; S H Shin
Journal:  Endocrine       Date:  1997-12       Impact factor: 3.633

7.  Prolactin and fMRI response to SKF38393 in the baboon.

Authors:  Brad Miller; Lauren A Marks; Jonathan M Koller; Blake J Newman; G Larry Bretthorst; Kevin J Black
Journal:  PeerJ       Date:  2013-10-29       Impact factor: 2.984

8.  Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration.

Authors:  Mark N Stein; Jyoti Malhotra; Rohinton S Tarapore; Usha Malhotra; Ann W Silk; Nancy Chan; Lorna Rodriguez; Joseph Aisner; Robert D Aiken; Tina Mayer; Bruce G Haffty; Jenna H Newman; Salvatore M Aspromonte; Praveen K Bommareddy; Ricardo Estupinian; Charles B Chesson; Evita T Sadimin; Shengguo Li; Daniel J Medina; Tracie Saunders; Melissa Frankel; Aparna Kareddula; Sherrie Damare; Elayne Wesolowsky; Christian Gabel; Wafik S El-Deiry; Varun V Prabhu; Joshua E Allen; Martin Stogniew; Wolfgang Oster; Joseph R Bertino; Steven K Libutti; Janice M Mehnert; Andrew Zloza
Journal:  J Immunother Cancer       Date:  2019-05-22       Impact factor: 13.751

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.